Record: found
Abstract: found
Article: not found

Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.

Author(s): Seyed Mahmoudpour, Maarten Leusink, Lisa van der Putten, Ingrid Terreehorst, Folkert W. Asselbergs, Anthonius de Boer, Anke H. Maitland-van der Zee

Publication date: 2013-01-31

Journal: Pharmacogenetics

Keywords: Adult, Aged, Angioedema, chemically induced, Angiotensin-Converting Enzyme Inhibitors, adverse effects, Cough, Female, Humans, Male, Middle Aged, Peptidyl-Dipeptidase A, genetics, Pharmacogenetics, Polymorphism, Genetic, Receptor, Bradykinin B2

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Angioedema and cough are the two most important adverse effects of ACE inhibitors (ACEIs). Evidence exists that ACEI-related angioedema/cough is partly genetically determined and several genes have been identified to play a role in the development of ACEI-related adverse effects. This study was performed in order to evaluate the evidence of these genetic associations and ACEIs' adverse effects. After removing duplicates and critical appraisal, 19 studies were considered to be eligible to review; 14 articles about cough and five articles about angioedema. A separate meta-analysis was performed for the most studied ACE insertion/deletion polymorphism (rs4646994) and its association with cough. One gene region (XPNPEP2) was associated with ACEI-induced angioedema in three studies. In our meta-analysis we did not find a significant association between the ACE insertion/deletion polymorphism and ACEI cough.